[Alpha Biz= Reporter Kim Sangjin] Dongkoo Bio Pharmaceutical announced on the 28th that it will face a suspension of manufacturing operations due to a violation of drug laws. The suspension amount is 131.4 billion won, which corresponds to 61.16% of the company's recent sales. The suspension will take effect on September 10.
The suspension details are as follows:
Suspension of manufacturing for the specific formulation (tablets) for 1 month (September 10 to October 9)
Suspension of manufacturing for Glipam 2/500mg tablets for 5 months (September 10 to February 9 of the following year)
Suspension of manufacturing for Roxoris tablets (Loxoprofen Sodium Hydrate) for 3 months and 15 days (September 10 to December 24)
The company stated, “The administrative action is limited to the suspension of manufacturing, and the sale of existing product inventory will still be possible. We plan to use our current stock to prevent disruptions in medical settings, and the impact on our performance from reduced sales is expected to be minimal.” The company also added, “We will do our best to prevent future occurrences and ensure the supply of high-quality pharmaceuticals by complying with relevant laws and regulations.”
AlphaBIZ Kim SangJin(letyou@alphabiz.co.kr)
